Teva Pharmaceutical Industries (NYSE:TEVA) PT Raised to $17.00 at Barclays

Teva Pharmaceutical Industries (NYSE:TEVAGet Free Report) had its price objective upped by research analysts at Barclays from $15.00 to $17.00 in a research note issued to investors on Monday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price objective suggests a potential upside of 38.78% from the company’s previous close.

A number of other equities research analysts also recently issued reports on TEVA. Jefferies Financial Group raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and boosted their price objective for the company from $10.00 to $14.00 in a research report on Tuesday, January 23rd. HSBC assumed coverage on shares of Teva Pharmaceutical Industries in a research report on Monday, December 18th. They set a “buy” rating and a $13.00 price objective for the company. Piper Sandler raised shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and boosted their price objective for the company from $8.00 to $12.00 in a research report on Wednesday, January 3rd. UBS Group raised shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and upped their target price for the stock from $11.00 to $13.00 in a report on Monday, November 27th. Finally, StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 1st. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $12.88.

Read Our Latest Stock Analysis on TEVA

Teva Pharmaceutical Industries Trading Down 1.1 %

NYSE:TEVA opened at $12.25 on Monday. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 2.46. Teva Pharmaceutical Industries has a 12 month low of $7.09 and a 12 month high of $12.64. The company has a market cap of $13.73 billion, a PE ratio of -26.06, a price-to-earnings-growth ratio of 1.41 and a beta of 1.01. The company has a 50 day simple moving average of $10.84 and a two-hundred day simple moving average of $9.85.

Teva Pharmaceutical Industries (NYSE:TEVAGet Free Report) last posted its earnings results on Wednesday, November 8th. The company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.03. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive return on equity of 35.10%. The business had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.73 billion. During the same quarter in the previous year, the firm posted $0.56 EPS. The firm’s revenue was up 8.3% on a year-over-year basis. Research analysts forecast that Teva Pharmaceutical Industries will post 2.3 earnings per share for the current year.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 31,766 shares of the firm’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $12.37, for a total value of $392,945.42. Following the completion of the sale, the chief accounting officer now owns 10,676 shares of the company’s stock, valued at $132,062.12. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.62% of the stock is owned by insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Institutional investors have recently modified their holdings of the stock. Los Angeles Capital Management LLC purchased a new position in Teva Pharmaceutical Industries during the third quarter valued at approximately $3,000,000. Camber Capital Management LP increased its holdings in Teva Pharmaceutical Industries by 183.3% during the second quarter. Camber Capital Management LP now owns 8,500,000 shares of the company’s stock valued at $64,005,000 after buying an additional 5,500,000 shares during the period. Harel Insurance Investments & Financial Services Ltd. boosted its stake in Teva Pharmaceutical Industries by 184,642.3% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 27,711,340 shares of the company’s stock valued at $282,656,000 after acquiring an additional 27,696,340 shares in the last quarter. Affinity Asset Advisors LLC acquired a new stake in Teva Pharmaceutical Industries in the second quarter valued at approximately $12,048,000. Finally, Capital Fund Management S.A. boosted its stake in Teva Pharmaceutical Industries by 108.3% in the second quarter. Capital Fund Management S.A. now owns 1,361,793 shares of the company’s stock valued at $10,254,000 after acquiring an additional 707,901 shares in the last quarter. 43.23% of the stock is owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

(Get Free Report)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.

Read More

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.